ESBATech, now a Novartis company, is recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications. The most advanced product from the ESBATech platform received marked approval by the FDA in October 2019 and shortly thereafter in all major markets.

Award
  • Nominated in 2020

  • Winner in 2021